A randomised controlled trial of eicosapentaenoic acid (EPA) and/or aspirin for colorectal adenoma (or polyp) preve
Lead Research Organisation:
University of Leeds
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
Scientific Abstract
Research design: A randomised, double-blind, placebo-controlled 2 x 2 factorial trials integrated into the screening and surveillance phases of the National Bowel Cancer Screening Programme (BCSP).
Study population: BCSP patients str
Research design: A randomised, double-blind, placebo-controlled 2 x 2 factorial trials integrated into the screening and surveillance phases of the National Bowel Cancer Screening Programme (BCSP).
Study population: BCSP patients str
Organisations
- University of Leeds (Lead Research Organisation)
- University of Sussex (Collaboration)
- Thetis Pharmaceuticals LLC (Collaboration)
- Igennus Healthcare Nutrition (Collaboration)
- Penn State University (Collaboration)
- The University of Texas at San Antonio (Collaboration)
- Medical Research Council (MRC) (Collaboration)
- UNIVERSITY OF BRADFORD (Collaboration)
- University of Bologna (Collaboration)
People |
ORCID iD |
Publications
Burr N
(2013)
Commentary: the association between low-dose aspirin use and the incidence of colorectal cancer.
in Alimentary pharmacology & therapeutics
Gill MD
(2014)
Screen-detected colorectal cancers are associated with an improved outcome compared with stage-matched interval cancers.
in British journal of cancer
Hull M
(2019)
Eicosapentaenoic acid and/or aspirin for preventing colorectal adenomas during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: the seAFOod RCT
in Efficacy and Mechanism Evaluation
Hull M
(2015)
Successful delivery of clinical gastroenterology studies in the UK
in Gut
Hull MA
(2020)
A risk-stratified approach to colorectal cancer prevention and diagnosis.
in Nature reviews. Gastroenterology & hepatology
Nakanishi M
(2018)
A novel bioactive derivative of eicosapentaenoic acid (EPA) suppresses intestinal tumor development in Apc?14/+ mice.
in Carcinogenesis
Sprange K
(2015)
No drug, no trial? Think again!
in Trials
| Description | COLO-PREVENT: A platform for developing COLOrectal cancer PREVENTion therapies |
| Amount | £6,228,662 (GBP) |
| Funding ID | A29542: CRUK/19/011 |
| Organisation | University of Leicester |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2021 |
| End | 03/2031 |
| Description | Project Grant |
| Amount | £1,496,870 (GBP) |
| Organisation | Yorkshire Cancer Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 09/2020 |
| Description | Project grant scheme |
| Amount | £11,000 (GBP) |
| Organisation | Leeds Teaching Hospitals NHS Trust |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 08/2015 |
| Description | STudy Of Prevention by Aspirin anD EPA; kNowledge Of Mechanism of Action (STOP-ADENOMA) |
| Amount | £532,246 (GBP) |
| Funding ID | NIHR128210 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 08/2021 |
| Description | Yorkshire Cancer Research Project Grant |
| Amount | £216,941 (GBP) |
| Organisation | Yorkshire Cancer Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2011 |
| End | 04/2014 |
| Description | Consultancy for Thetis Pharma |
| Organisation | Thetis Pharmaceuticals LLC |
| Country | United States |
| Sector | Private |
| PI Contribution | Advice on design of pre-clinical and clinical studies for omega-3 derivative IMP. Contribution to pre-clinical investigation of TP-252 efficacy for prevention of intestinal tumorigenesis in ApcD14 model. Data on the omega-3 EPA effect on immune checkpoint inhibition treatment of colorectal cancer shared with Thetis along with discussion of Thetis data on the topic to forge a further experimental collaboration |
| Collaborator Contribution | Sharing of data. Provision of TP-317 (RvE1 salt) and access to RvE1 measurements which will help STOP-ADENOMA project |
| Impact | Carcinogenesis 2017; doi: 10.1093/carcin/bgx136 |
| Start Year | 2016 |
| Description | FADS genetic analysis |
| Organisation | University of Texas |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Provision of seAFOod trial DNA samples and accompanying SNP analysis from STOP-ADENOMA for comparison with a polymorphism assay performed by Dr Kothapalli and Dr Brenna in Austin, Texas |
| Collaborator Contribution | indel polymorphism (rs66698963) measurement on DNA samples |
| Impact | work ongoing |
| Start Year | 2021 |
| Description | lipidomic analysis |
| Organisation | Penn State University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | seAFOod trial plasma samples for lipidomic analysis in parallel with STOP-ADENOMA analysis |
| Collaborator Contribution | lipidomic analysis focusing on oxylipins (SPMs) |
| Impact | none yet |
| Start Year | 2020 |
| Description | partnership with Igennus Healthcare Nutrition |
| Organisation | Igennus Healthcare Nutrition |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We obtained active EPA and placebo capsules from Igennus at cost price after the previous supplier to the seAFOod Trial (SLA Pharma AG) was unable to continue to supply IMP free of charge. |
| Collaborator Contribution | Discount purchase of capsules and support developing MHRA CTA amendment |
| Impact | supply of capsules for continued recruitment |
| Start Year | 2014 |
| Description | seAFOod Trial Biomarker analysis |
| Organisation | University of Bologna |
| Department | Department of Gastroenterology |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | study design, sample collection and Trial organisation |
| Collaborator Contribution | biological sample handling, fatty acid measurement and lipidomic analyses |
| Impact | Neoplasia 2010;12:618-27; Br J Pharmacol 2012;166:1724-37; J Chromatogr B Analyt Technol Biomed Life Sci 2017;1055-1056:125-134; Prostaglandins Leukotrienes Essential Fatty Acids 2016;115:60-66; Gut 2017 DOI:10.1136/gutjnl-2017-314968 |
| Start Year | 2009 |
| Description | seAFOod Trial Biomarker analysis |
| Organisation | University of Bradford |
| Department | Institute of Cancer Therapeutics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | study design, sample collection and Trial organisation |
| Collaborator Contribution | biological sample handling, fatty acid measurement and lipidomic analyses |
| Impact | Neoplasia 2010;12:618-27; Br J Pharmacol 2012;166:1724-37; J Chromatogr B Analyt Technol Biomed Life Sci 2017;1055-1056:125-134; Prostaglandins Leukotrienes Essential Fatty Acids 2016;115:60-66; Gut 2017 DOI:10.1136/gutjnl-2017-314968 |
| Start Year | 2009 |
| Description | seAFOod Trial TTR |
| Organisation | University of Sussex |
| Department | School of Business, Management and Economics Sussex |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Contributed to MRC request to add to Tracking Translational Research project by Dr Michael Hopkins |
| Collaborator Contribution | Interviews with me and collaborators |
| Impact | nil |
| Start Year | 2015 |
| Description | seaFOod Trial link with MRC START programme to test improved materials for trial recruitment |
| Organisation | Medical Research Council (MRC) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Cluster randomised sites to use of multimedia materials for particpant recruitment within the seAFOod Trial |
| Collaborator Contribution | worked with MRC START team to develop video and website material and submitted SA to REC. |
| Impact | nil |
| Start Year | 2014 |
| Description | Blogs x 2 about trial results |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Blogs about trial results for PHE Bowel Cancer Screening and Bowel Cancer UK Charity |
| Year(s) Of Engagement Activity | 2018 |
| Description | International Aspirin Foundation meeting 2018 talk |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | seAFOod Trial results presented at International Aspirin Foundation meeting September 2018, Edinburgh |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://gallery.mailchimp.com/9711726f12cfa7b1da57e7108/files/423036d6-6418-4309-94f7-c5fa04e1ac7f/C... |
| Description | Press release about Trial funding |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Primary Audience | Public/other audiences |
| Results and Impact | written and audio media none recognised |
| Year(s) Of Engagement Activity | 2010 |
| Description | Public information website |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | CancerHelpUK information about seAFOod Trial increased public (patient) awareness of Trial |
| Year(s) Of Engagement Activity | 2012 |